BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Thursday reported a loss of $120.4 million in its second quarter.
On a per-share basis, the Boulder, Colorado-based company said it had a loss of $2.27.
The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.70 per share.
The biopharmaceutical company posted revenue of $33 million in the period, which also did not meet Street forecasts. Five analysts surveyed by Zacks expected $34.9 million.
Clovis shares have dropped 41% since the beginning of the year. The stock has dropped 76% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLVS at https://www.zacks.com/ap/CLVS
all right reserved for yahoo news